

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stefan Golz, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP03/02688

Title: Diagnostics and Therapeutics for Diseases Associated with Growth Hormone Secretagogue Receptor (GHS)

**MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449. A copy of the International Search Report is also enclosed for your reference.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Susan M. Pellegrino
Reg. No.: 48,972
Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Telephone: (203) 812-6450
Facsimile: (203) 812-6459

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Serial No.		Art Unit		Filing Date		App. No. Le A 35 943				
INFORMATION DISCLOSURE CITATION				Applicant(s) Stefan GOLZ, et al.										
U.S. PATENT DOCUMENTS														
*		DOCUMENT NO.							DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS														
*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
	F1	0	1	9	2	2	9	2	06/12/01	WO			YES	NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)														
R1	Bednarek, M. A., et al., "Structure-Function Studies on the New Growth Hormone-Releasing Peptide, Ghrelin: Minimal Sequence of Ghrelin Necessary for Activation of Growth Hormone Secretagogue Receptor 1a", J. Med. Chem., <u>43</u> (23): 4370-4376 (October 2000)													
R2	Bodart, V., et al., "Identification and Characterization of a New Growth Hormone-Releasing Peptide in the Heart", Circulation Research, <u>85</u> (9): 796-802 (October 1999)													
R3	Katugampola, S. D., et al., "[¹²⁵ I-His ⁹]-Ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue; up-regulation of receptors with atherosclerosis", British Journal of Pharmacology, <u>134</u> (1): 143-149 (September 2001)													
R4	Nagaya, N., et al., "Hemodynamic and hormonal effects of human ghrelin in healthy volunteers", Am. J. Physiol. Regulatory Integrative Comp. Physiol., <u>280</u> (5): R1483-R1487 (May 2001)													
EXAMINER										DATE CONSIDERED				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

SEP 2 2 2004